Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Rangering i aksjer #2258
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aksjekurs
$64.11
Markedsverdi
$8.91B
Endring (1 dag)
2.34%
Endring (1 år)
8.03%
Land
US
Handel Cytokinetics, Incorporated (CYTK)

Kategori

Healthcare
Historikk for aksjesplitt for Cytokinetics, Incorporated (CYTK)
Aksjen Cytokinetics, Incorporated (symbol: CYTK) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Jun 25, 2013.
Én CYTK-aksje kjøpt før Jun 25, 2013 tilsvarer i dag 0.16666666666667 CYTK-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL